IL-8 produced by human malignant melanoma cells in vitro is an essential autocrine growth factor.
Dirk Schadendorf(National Center for Tumor Diseases), B. M. Czarnetzki(Jüdisches Krankenhaus Berlin), Michael Sticherling(Universitätsklinikum Erlangen), Bernd Algermissen(Jüdisches Krankenhaus Berlin), Margitta Worm(Charité - Universitätsmedizin Berlin), A. Möller(Jüdisches Krankenhaus Berlin)
Cited by 408
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma
|Journal of Clinical Oncology|2015|2.1k
Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis
|New England Journal of Medicine|2016|2k
Adjuvant Dabrafenib plus Trametinib in Stage III<i>BRAF</i>-Mutated Melanoma
|New England Journal of Medicine|2017|1.5k